missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ Golimumab Recombinant Monoclonal Antibody
GREENER_CHOICE

Product Code. 30283393
Change view
Click to view available options
Quantity:
1 mg
100 μg
Unit Size:
100µg
1mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Product Code. Quantity unitSize
30283393 100 μg 100µg
30283436 1 mg 1mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
This item is not returnable. View return policy
Product Code. 30283393 Supplier Invitrogen™ Supplier No. MA559395

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Recombinant Monoclonal Antibody

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Golimumab is a human IgG1kappa monoclonal antibody derived from immunizing genetically engineered mice with human TNFalpha. Golimumab binds and inhibits soluble and transmembrane human TNFalpha. Increased TNFalpha is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U. S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFalpha. Inhibition of TNFalpha prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Golimumab
Applications ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
Classification Recombinant Monoclonal
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Gene Alias CNTO 148; Simponi
Host Species Human
Purification Method Protein A
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Lyophilized
Isotype IgG1
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.